Cutaneous and pulmonary manifestations of sarcoidosis triggered by coronavirus disease 2019 infection

Rodrigues, Felipe Tavares; Quirino, Renata Miguel; Gripp, Alexandre Carlos

doi:10.1590/0037-8682-0647-2021

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Onset Of Sarcoidosis During or After Covid-19supporting

confidence: 55%

“…However, no SARS-CoV-2 RNA was detected in the affected areas (30). Similar symmetrical erythematous non-pruritic papules and plaques were observed in a 57-year-old COVID-19 convalescent woman who was found to have sarcoid granulomas after histological examination of a skin biopsy (33). Some patients were noted to have bilateral lymphadenopathy affecting hilar, paratracheal, and subcarinal lymph nodes based on chest CT scans performed 10 weeks after COVID-19.…”

Section: Review Analysis Methodsmentioning

confidence: 61%

See 1 more Smart Citation

Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients

Rubinstein,

Kudryavtsev,

Malkova

et al. 2023

Front. Med.

View full text Add to dashboard Cite

Currently, there are a large number of reports about the development of autoimmune conditions after COVID-19. Also, there have been cases of sarcoid-like granulomas in convalescents as a part of the post-COVID-19 syndrome. Since one of the etiological theories of sarcoidosis considers it to be an autoimmune disease, we decided to study changes in the adaptive humoral immune response in sarcoidosis and SARS-CoV-2 infection and to find out whether COVID-19 can provoke the development of sarcoidosis. This review discusses histological changes in lymphoid organs in sarcoidosis and COVID-19, changes in B cell subpopulations, T-follicular helper cells (Tfh), and T-follicular regulatory cells (Tfr), and analyzes various autoantibodies detected in these pathologies. Based on the data studied, we concluded that SARS-CoV-2 infection may cause the development of autoimmune pathologies, in particular contributing to the onset of sarcoidosis in convalescents.

show abstract

Section: Onset Of Sarcoidosis During or After Covid-19supporting

confidence: 55%

Section: Review Analysis Methodsmentioning

confidence: 61%

Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients

Rubinstein,

Kudryavtsev,

Malkova

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…In the context of molecular mimicry (3), the development of sarcoidosis after past Covid-19 (4,5) or after/within vaccination for Covid-19 (6)(7)(8)(9)(10) should not be surprising and has been described repeatedly in the scientific literature (4-10). The leading connection in the molecular mimicry hypothesis, as a generator of a cross-mediated immune response in sarcoidosis/sarcoid-type reactions, appears to be the incorporation of both infectious/immunogenic (fresh Covid-19 infection) and the still immunogenic but non-infectious material (vaccination for Covid-19), (2,3).…”

Section: Discussionmentioning

confidence: 99%

First reported case of erythrodermic sarcoidosis with systemic involvement during vaccination for Covid-19

Tchernev¹,

Kordeva²,

Kirilova³

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

Post-vaccinal and parainfectious activation of the immunity with subsequent development of a certain immunological/skin-immunological disease isn’t rare in the clinical practice. This concept is mentioned in relation to molecular/antigenic mimicry. To this day, the pathogenesis of sarcoidosis and sarcoid-type reactions remains a mystery. Moreover, they can be a warning sign of changes in tissue homeostasis, whether it is infectious, non-infectious-immunological, tumor-related, etc. We present a rare form of erythrodermic sarcoidosis with massive systemic involvement (pericarditis, supraventricular tachycardia, hepatitis, iritis/iridocyclitis, pulmonary fibrosis/bihilar lymphadenopathy, and arthritis) developed after receiving the ChadOx1-S vaccine for Covid-19. Systemic immunosuppressive therapy with Methylprednisolone was introduced according to a scheme (in a reduction mode with an initial dose of 40 mg/day intravenously) in combination with: topical Pimecrolimus 1% cream twice a day. Rapid improvement of the symptoms was observed within the first two days of treatment. According to the references in the scientific literature, the presented patient turns out to be the first case of erythrodermic sarcoidosis (with systemic involvement), described as a side effect after vaccination and/or administration of a certain medicinal form.

show abstract

“…and sarcoidosis [149][150][151][152][153][154]. Either we regard these events as random and coincidental or we must accept the primacy of inflammation in both forms of disease.…”

Section: The Many Faces Of Inflammationmentioning

confidence: 99%

Energy Dynamics in the Autoimmune Disorders: The Unity of Immunity

Thorp,

Northrup

et al. 2023

G Med Sci

View full text Add to dashboard Cite

In this paper we examine the autoimmune disorders (AIDs) not from a cellular/ molecular standpoint as scientists have attempted for decades but from a dynamic energy-based perspective. Not only does this framework account for the origins of these disorders but it explains phenomena that cell-based mechanisms cannot. In addition, we examine the historical basis of 20th century immune theory and point to serious errors in the research literature that have lain unrecognized for over a century and which led to broad misconception of immune functions.

show abstract

Cutaneous and pulmonary manifestations of sarcoidosis triggered by coronavirus disease 2019 infection

Cited by 4 publications

References 3 publications

Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients

Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients

First reported case of erythrodermic sarcoidosis with systemic involvement during vaccination for Covid-19

Energy Dynamics in the Autoimmune Disorders: The Unity of Immunity

Contact Info

Product

Resources

About